Health
Study shows reliability and robustness of injectable anti-obesity medication – News-Medical.Net
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing…
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the Journal of the American Medical Association.
The 68-week study was conducted at 41 sites in the…
-
Business14 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News14 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News14 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots
-
Business18 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?